Aldeyra Therapeutics Inc(ALDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.38 | Insider Own | 3.7% | Shs Outstand | 60.3M | Perf Week | -7.2% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 18.24% | Insider Trans | 12.61% | Shs Float | 58.1M | Perf Month | -46.75% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.09 | Inst Own | 60.65% | Short Float | 5.97% | Perf Quarter | -59.01% |
| Income | -0.02B | P/S | - | EPS this Y | 39.29% | Inst Trans | -3.94% | Short Ratio | 2.97 | Perf Half Y | -58.08% |
| Sales | 0.00B | P/B | 1.03 | EPS next 5Y | 36.26% | ROA | -34.8% | Short Interest | 3.47M | Perf YTD | -87.46% |
| Book/sh | 0.63 | P/C | 0.87 | EPS past 3/5Y | 19.04% 12.61% | ROE | -49.48% | 52W High | -89.04% ($5.93) | Perf Year | -87.46% |
| Cash/sh | 0.75 | P/FCF | - | Sales past 3/5Y | - | ROIC | -60.85% | 52W Low | 3.49% ($0.63) | Perf 3Y | -56.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 54.84% | Gross Margin | - | Volatility(W/M) | 12.79% 12.11% | Perf 5Y | -91.91% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | -90.46% |
| Dividend Ex-Date | - | Quick Ratio | 4.84 | EPS Q/Q | 44.44% | Profit Margin | - | RSI (14) | 25.7 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.84 | Sales Q/Q | - | SMA20 | -28.72% ($0.91) | Beta | 1.26 | Target Price | $6.6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/07/31 | SMA50 | -47.5% ($1.24) | Rel Volume | 0.7 | Prev Close | $0.65 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -16.13% - | SMA200 | -72.55% ($2.37) | Avg Volume(3M) | 1.17M | Price | $0.65 |
| IPO | 2014/5/2 | Option/Short | Yes/Yes | Trades | 2271 | Volume | 821,855 | Change | 0.68% |
🧬 Aldeyra Therapeutics is a clinical-stage biotech developing treatments for ophthalmic and systemic inflammatory diseases based on a mechanism that modulates reactive aldehyde species (RASP). Its lead pipeline candidate is reproxalap, being developed for dry eye disease, along with candidates for rare ophthalmic diseases such as retinitis pigmentosa. The company is headquartered in the United States.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
ALDX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.3% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 60.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #435 of 595 in the industry
Based on market cap of $39M.
GRDX#432 GridAI Technologies Corp $40M PER - 
ATHE#433 Alterity Therapeutics Ltd ADR $40M PER - 
TIL#434 Instil Bio Inc $40M PER - ALDX#435 Aldeyra Therapeutics Inc $39M PER - 
VERU#436 Veru Inc $38M PER - 
FAQ
What kind of company is ALDX?
ALDX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALDX?
The market cap of ALDX is approximately $39M, ranking 4,973 within its sector.
What is the 52-week high and low for ALDX?
ALDX has recorded a 52-week high of $5.93 and a low of $0.63.
